PRESERVE WHAT MATTERS TO YOUR CHILD AFFECTED BY DUCHENNE MUSCULAR DYSTROPHY
In a clinical trial of 196 boys aged 5 to 15 with Duchenne muscular dystrophy, the effectiveness and safety of EMFLAZA were compared with placebo (sugar pills)
EMFLAZA improved muscle strength at 12 weeks compared with placebo
EMFLAZA was numerically favored in timed measures of patient function in comparison with placebo
walk 30 feet
climb 4 stairs
These findings were not considered statistically significant. This means that because the two groups studied were not large enough, the results could have occurred by chance.